Overview

Safety, Tolerability and Pharmacokinetic Profile of M108 Monoclonal Antibody in Patients With Advanced Unresectable Solid Tumors in China

Status:
Recruiting
Trial end date:
2023-12-30
Target enrollment:
Participant gender:
Summary
M108 is a monoclonal antibody specific for gastric and gastroesophageal adenocarcinomas. The aim of this phase I study is to establish safety and Tolerability of different Dosage regimen in patients With Advanced Unresectable Solid Tumors in China.
Phase:
Phase 1
Details
Lead Sponsor:
FutureGen Biopharmaceutical (Beijing) Co., Ltd